SLC26A4 and prostate adenocarcinoma: Importantly, SLC26A4 consistently acted as a protective factor for PFI in TCGA-PRAD (p = 0.0003), MSKCC (p < 0.0001), and GSE116918 (p = 0.0014) cohorts (Fig. 8B).